Entero Therapeutics (ENTO) Competitors $0.38 0.00 (-0.73%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.37 -0.01 (-1.64%) As of 04/17/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. KPRX, OBSV, SNSE, AIMD, CARM, BCLI, INDP, OMGA, ADXN, and CYCNShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Kiora Pharmaceuticals (KPRX), ObsEva (OBSV), Sensei Biotherapeutics (SNSE), Ainos (AIMD), Carisma Therapeutics (CARM), Brainstorm Cell Therapeutics (BCLI), Indaptus Therapeutics (INDP), Omega Therapeutics (OMGA), Addex Therapeutics (ADXN), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Kiora Pharmaceuticals ObsEva Sensei Biotherapeutics Ainos Carisma Therapeutics Brainstorm Cell Therapeutics Indaptus Therapeutics Omega Therapeutics Addex Therapeutics Cyclerion Therapeutics Entero Therapeutics (NASDAQ:ENTO) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking. Do insiders & institutionals believe in ENTO or KPRX? 12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.5% of Entero Therapeutics shares are held by company insiders. Comparatively, 0.9% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate ENTO or KPRX? Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 258.42%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Entero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the MarketBeat Community believe in ENTO or KPRX? Kiora Pharmaceuticals received 18 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformEntero TherapeuticsN/AN/AKiora PharmaceuticalsOutperform Votes1875.00% Underperform Votes625.00% Is ENTO or KPRX more profitable? Kiora Pharmaceuticals' return on equity of 21.32% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entero TherapeuticsN/A -87.06% -12.01% Kiora Pharmaceuticals N/A 21.32%16.39% Which has more risk & volatility, ENTO or KPRX? Entero Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Does the media favor ENTO or KPRX? In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Entero Therapeutics. Kiora Pharmaceuticals' average media sentiment score of 1.00 beat Entero Therapeutics' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Entero Therapeutics Neutral Kiora Pharmaceuticals Positive Which has better earnings & valuation, ENTO or KPRX? Kiora Pharmaceuticals has higher revenue and earnings than Entero Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntero TherapeuticsN/AN/A-$15.80MN/AN/AKiora Pharmaceuticals$16M0.52-$12.51M$1.042.68 SummaryKiora Pharmaceuticals beats Entero Therapeutics on 13 of the 14 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80M$6.45B$5.31B$7.34BDividend YieldN/A3.21%5.45%4.34%P/E RatioN/A6.9221.9417.82Price / SalesN/A231.01380.6697.73Price / CashN/A65.6738.2534.64Price / Book0.165.936.453.98Net Income-$15.80M$143.22M$3.22B$247.81M7 Day Performance-7.08%1.15%0.74%0.28%1 Month Performance-37.59%-13.22%-9.66%-7.60%1 Year PerformanceN/A-8.51%11.81%1.49% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero Therapeutics0.5841 of 5 stars$0.38-0.7%N/AN/A$1.80MN/A0.009Positive NewsGap DownKPRXKiora Pharmaceuticals3.8933 of 5 stars$2.65+1.9%$10.00+277.4%-36.8%$7.95M$16M2.5510Positive NewsOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150SNSESensei Biotherapeutics3.9 of 5 stars$0.30-0.5%$4.25+1,323.3%-58.2%$7.53MN/A-0.2540Gap DownAIMDAinos0.9284 of 5 stars$0.48-3.4%N/A-46.6%$7.42M$20,729.00-0.2940Short Interest ↓News CoverageGap UpCARMCarisma Therapeutics2.3761 of 5 stars$0.18-8.8%$2.74+1,456.8%-88.2%$7.36M$19.63M-0.1120Gap DownBCLIBrainstorm Cell Therapeutics3.5998 of 5 stars$1.09-2.7%$30.00+2,652.3%-89.0%$7.11MN/A-0.2340Analyst ForecastGap UpINDPIndaptus Therapeutics2.4656 of 5 stars$0.49+3.1%$8.50+1,635.0%-79.9%$7.07MN/A-0.296Gap DownOMGAOmega Therapeutics1.8662 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.8%$6.92M$8.10M-0.09120Gap UpADXNAddex Therapeutics1.7239 of 5 stars$6.51-9.1%$30.00+360.8%-62.1%$6.90M$556,045.00-19.1530Gap DownCYCNCyclerion Therapeutics2.3822 of 5 stars$2.52+2.0%N/A-21.4%$6.83M$2M-2.0730Gap Up Related Companies and Tools Related Companies Kiora Pharmaceuticals Competitors ObsEva Competitors Sensei Biotherapeutics Competitors Ainos Competitors Carisma Therapeutics Competitors Brainstorm Cell Therapeutics Competitors Indaptus Therapeutics Competitors Omega Therapeutics Competitors Addex Therapeutics Competitors Cyclerion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENTO Stock Free ENTO Stock Alerts